PNC Financial Services Group
APRE icon

PNC Financial Services Group’s Aprea Therapeutics APRE Stock Holding History

PNC Financial Services Group’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,000
Closed -$4.07K – 4781
2024
Q2 		$4.07K Hold
1,000
– – ﹤0.01% 4052
2024
Q1 		$6.69K Hold
1,000
– – ﹤0.01% 3875
2023
Q4 		$4.7K Hold
1,000
– – ﹤0.01% 3957
2023
Q3 		$4.17K Hold
1,000
– – ﹤0.01% 4038
2023
Q2 		$3.15K Hold
1,000
– – ﹤0.01% 4239
2023
Q1 		$4.44K Hold
1,000
– – ﹤0.01% 4077
2022
Q4 		$6.62K Hold
1,000
– – ﹤0.01% 3901
2022
Q3 		$13K Hold
1,000
– – ﹤0.01% 3633
2022
Q2 		$15K Buy
+1,000
New +$23.1K ﹤0.01% 3614
2020
Q4 		– Sell
-100
Closed -$48K – 3955
2020
Q3 		$48K Hold
100
– – ﹤0.01% 2758
2020
Q2 		$78K Buy
+100
New +$65.6K ﹤0.01% 2479

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PNC Financial Services Group's APRE Position: Q3 2024 in Review

PNC Financial Services Group sold out of Aprea Therapeutics (APRE) in Q3 2024, closing a stake of 1,000 shares — an estimated $4.07K sold.

PNC Financial Services Group first reported a position in APRE in Q2 2020 and held it in 11 quarters. The position peaked at $78K in Q2 2020. 22 funds tracked by Wall St. Rank hold APRE as of Q3 2024.

  • PNC Financial Services Group reported no remaining Aprea Therapeutics position as of Q3 2024 after selling out during the quarter.
  • PNC Financial Services Group sold 1,000 Aprea Therapeutics shares in Q3 2024, an estimated $4.07K.
  • PNC Financial Services Group first reported a position in Aprea Therapeutics in Q2 2020 and held it in 11 quarters.
  • PNC Financial Services Group's Aprea Therapeutics position peaked at $78K in Q2 2020.
  • 22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2024.

Based on PNC Financial Services Group's 13F filing for Q3 2024, filed 8 Nov 2024.